Online Forums

Our 5th annual update with EcoFact on global regulatory and ESG policy developments and trends salient for the biopharma sector. The discussion focuses on topics where ESG policy and regulation is evolving rapidly and the changes will affect biopharma companies, directly or indirectly. Members: Request link to Forum Presentation or Video

International Federation of Pharmaceutical Wholesalers (IFPW) — A conversation about their new ESG Framework for Healthcare. In early 2023, IFPW launched its ESG Framework for Healthcare to help create global alignment and consistency across the pharmaceutical sector on how to effectively communicate and report the impact of environmental, social, and corporate governance initiatives that advance the supply chain. Members: Request link to Forum Presentation

Bob Eccles, Visiting Professor of Management Practice, Saïd Business School, University of Oxford; Founding Chairman of SASB Request link to Forum Presentation

Dennis Ostwald, CEO of the WifOR Institute, and Sonja Haut, Head Impact Valuation at Novartis, take us on a deep dive into health from the perspective of its economic impact, how Novartis is implementing impact valuation, and what this approach could mean for the Biopharma sector. Request link to Forum Presentation

Jens Reissmann, Project Lead for EU Taxonomy Reporting at Bayer, shared insights and practical learnings from Bayer’s work on fulfilling these critical new reporting requirements, and put it into the wider context of embedding Sustainability/ESG in management accounting, and preparing for ‘still to come’ external disclosure requirements.

ESG Standards and Regulatory Progress with ECOFACT, an update on global policy developments around ESG that will affect biopharma directly or indirectly in the near-term. Fourth in an ongoing series tailored for BSRT participants. Request link to Forum Presentation

Health Outcomes Observatory (H2O) with Meni Styliadou, H2O Founder and Co-Leader, Distinguished Fellow of the Data Sciences Institute and VP of Government Affairs, Public Policy, and Sustainable Healthcare at Takeda. In conversation with Francesco Patalano, H2O Working Group Leader and Head of Pediatric and Patient Reported Outcomes Centers of Excellence at Novartis, and Madeleine Brady, H2O Communications (Moderator). Request link to Forum Presentation

20+ Years of Sustainability Leadership – A conversation with Lars Rebien Sørensen

Continuing the dialog between biopharma leaders and capital markets representatives on how to structure effective, efficient, and decision-useful communications about ESG strategy and performance.

Towards a global perspective on Biopharma sustainability, hosted by the ESG Disclosure Study Group, Japan.

Update on global hard and soft regulatory changes affecting biopharma.Focus on EU: Green Deal, Circular Economy, Sustainable Finance, Non-Financial Reporting Directive.Speaker: Olivier Jaeggi, Managing Director, ECO:FACT Request link to Forum Presentation

Roundtable Forum with Lise Kingo.Biopharma sustainability oversight and governance priorities.Speaker: Lise Kingo, Independent Director, Sanofi; former Executive Director, UN Global Compact Request link to Forum Presentation